Drugdiscovery >> Drugs >> News
4543
Views
FDA approves Adempas for the treatment of two forms of pulmonary hypertension - drugdiscovery.com
FDA approves Adempas for the treatment of two forms of pulmonary hypertension - drugdiscovery.com


Bayer HealthCare’s drug Adempas (riociguat) is approved by the FDA for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH. The second indication is pulmonary arterial hypertension (PAH) in adults.
Read More >>


Tags: Adempas, riociguat, treatment, drug, pulmonary hypertension, pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension - October 9, 2013
Related Articles
5922
Views
Bayer's hypertension drug Adempas approved in Canada Bayer's hypertension drug Adempas approved in Canada
The Health Canada has approved the drug Adempas (riociguat) for the treatment of a severe, progressive and life-threatening condition of the heart and lungs, chronic thromboembolic pulmonary hypertens Read More >>

Tags: Adempas, riociguat, Bayer, hypertension drug, thromboembolic, pulmonary hypertension, Canada, approval

6597
Views
Bayer's riociguat approved in two pulmonary hypertension indications Bayer's riociguat approved in two pulmonary hypertension indications
FDA has backed approval of the drug for the treatment of both pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Read More >>

Tags: FDA, approval, Bayer, riociguat, indication, pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension

5338
Views
Orphan drug designation for Bayer’s hypertension drug riociguat Orphan drug designation for Bayer’s hypertension drug riociguat
The FDA has granted two separate orphan drug designations for riociguat, Bayer’s investigational hypertension drug, for the treatment of pulmonary arterial hypertension and chronic thromboembolic pu Read More >>

Tags: riociguat, hypertension, drug, orphan drug designation, orphan, Bayer, pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension

13565
Views
Bayer’s new hypertension drug to be approved by FDA Bayer’s new hypertension drug to be approved by FDA
The new drug worked well in clinical trials and is recommended for approval but at lower doses than those proposed by the company. Read More >>

Tags: Bayer, new drug, hypertension, pulmonary hypertension

4291
Views
FDA approves dolutegravir for the treatment of HIV-1 FDA approves dolutegravir for the treatment of HIV-1
After a successful phase III clinical trial, ViiV Healthcare’s drug Tivicay (dolutegravir) has been approved for the treatment of HIV-1 in combination with other antiretroviral agents, in adults an Read More >>

Tags: dolutegravir, tivicay, ViiV Healthcare, HIV, HIV-1, treatment

4109
Views
Gilenya reduces brain volume loss in patients with relapsing forms of multiple sclerosis Gilenya reduces brain volume loss in patients with relapsing forms of multiple sclerosis
The data from several studies that took place over four years show that Novartis’ MS drug Gilenya both reduces brain volume loss and slows the disability progression in patients with multiple sclero Read More >>

Tags: Gilenya, MS, multiple sclerosis, relapsing form, treatment, drug

4944
Views
FDA approves Abraxane combo for pancreatic cancer FDA approves Abraxane combo for pancreatic cancer
Celgene’s Abraxane (paclitaxel protein-bound particles for injectable suspension) has been approved by the FDA as a first–line treatment for patients with metastatic adenocarcinoma of the pancreas Read More >>

Tags: pancreatic cancer, treatment, adenocarcinoma of the pancreas, abraxane, gemcitabine, FDA approval, Celgene

3528
Views
FDA approves Trokendi XR for the treatment of epilepsy FDA approves Trokendi XR for the treatment of epilepsy
Supernus Pharmaceuticals announced the FDA’s approval of Trokendi XR , an extended-release treatment for epilepsy that is taken once daily. It will be its second epilepsy drug to hit the market this Read More >>

Tags: Trokendi XR, epilepsy, supernus pharmaceuticals, supernus, drug approval, FDA

3846
Views
FDA approves Cimzia for the treatment of psoriatic arthritis FDA approves Cimzia for the treatment of psoriatic arthritis
After a successful Phase 3 trial, Cimzia (certolizumab pegol) is now approved for the treatment of psoriatic arthritis. The drug is already being used in the US for the treatment of rheumatoid arthrit Read More >>

Tags: Cimzia, psoriatic arthritis, certolizumab pegol, FDA

5475
Views
FDA Approves Fetzima for the treatment of Major Depressive Disorder (MDD) in adults FDA Approves Fetzima for the treatment of Major Depressive Disorder (MDD) in adults
Forest Laboratories, Inc. and Pierre Fabre Laboratories announced on July 25, that Fetzima (levomilnacipran extended-release capsules), a once-daily serotonin and norepinephrine reuptake inhibitor (SN Read More >>

Tags: Fetzima, Major Depressive Disorder, drug approval

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013